DiaMedica Therapeutics Inc
diamedica.comWhat Do They Do?
Develops recombinant protein drug candidates intended to treat preeclampsia, fetal growth restriction and acute ischemic stroke, with a planned program for severe acute pancreatitis.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$10.1MView ↗
- ▲ +32% (Loss)
- vs −$7.7M in Q2 FY2025
Treatment focus The earlier report focused the lead candidate on acute ischemic stroke and chronic kidney disease; the latest centers its clinical programs on preeclampsia, fetal growth restriction and acute ischemic stroke.
Another candidate's potential use
The earlier report described a potential treatment for inflammatory diseases; the latest describes a potential treatment for severe acute pancreatitis.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 30, 2026We are a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s…View ↗
We are a clinical stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with a…View ↗
Who Do They Compete With?
Competes with Comanche Biopharma, Basking Biosciences, Translational Sciences, Pharmazz, Simcere Pharmaceutical Group, Lumosa Therapeutics, Bayer, Janssen, and BMS
10-K for FY2025, filed Mar 30, 2026There are currently no FDA-approved treatments for preeclampsia and only a limited number of therapeutics in development. Metformin, an…View ↗
Loading...
